Antikoagulation und Thrombozytenhemmung beim akuten Koronarsyndrom – Triple-Therapie

Zusammenfassung

Die Behandlung von Patienten, die sich mit einem akuten Koronarsyndrom (ACS) und gleichzeitig bestehender Indikation zur oralen Antikoagulation im klinischen Alltag präsentieren, stellt die Ärzte vor die schwierige Aufgabe, die medikamentöse Therapie balanciert zu etablieren und vor allem Blutungskomplikationen zu vermeiden. Dies betrifft im klinischen Alltag ungefähr 6–8 % der Patienten mit einem akuten Koronarsyndrom [10]. In der heutigen Zeit steht ein großes Portfolio an unterschiedlichen Substanzen zur Verfügung, um die duale Thrombozytenaggregationshemmung und die orale Antikoagulation zu etablieren. Um diese Herausforderung zu meistern, bedarf es entsprechender Kenntnisse im Bereich der unterschiedlichen Medikamentengruppen.

Abstract

The therapy of patients with acute coronary syndrome and simultaneously indication for oral anticoagulation is difficult to handle. The medical treatment must be selected well to avoid bleeding complications in these patients. About 6–8 % of the patients with acute coronary syndrome also need an oral anticoagulation therapy due to atrial fibrillation. Today a wide portfolio in inhibitors of platelet aggregation and oral anticoagulation medicine is given. This challenge needs knowledge on the subject of the different pharmaceutical agents.

Schlüsselwörter

Antikoagulation - Vorhofflimmern - akutes Koronarsyndrom - Vitamin-K-Antagonist - NOAC

Key words

oral anticoagulation - atrial fibrillation - acute coronary syndrome - vitamin K antagonist - NOAC

• Literatur

• 1 Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. Placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789
• 2 Dans AL, Connolly SJ, Wallentin L et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term-Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-640
• 3 Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708
• 4 Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19
• 5 Sarafoff N, Martischnig A, Wealer J et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and indication for oral anticoagulation. J Am Coll Cardiol 2013; 61: 2060-2066
• 6 Fu A, Singh K, Abunassar J et al. Ticagrelor in triple antithrombotic therapy: Predictors of ischemic and bleeding complications. Clin Cardiol 2016; 39: 19-23
• 7 Fiedler KA, Maeng M, Mehilli J et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015; 65: 1619-1629
• 8 Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 318: 1107-1115
• 9 Chen CF, Chen B, Zhu J et al. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulation treatment. A meta-analysis. Herz 2015; 40: 1070-1083
• 10 Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315